Cargando…

Cost effectiveness of interventions to improve adherence to statin therapy in ASCVD patients in the United States

INTRODUCTION: Cardiovascular disease (CVD) is the leading cause of death in the United States, and high cholesterol is a leading risk factor for CVD. While statins are effective at reducing cholesterol, they are frequently underused in patients at highest risk of CVD. The objective of this study was...

Descripción completa

Detalles Bibliográficos
Autores principales:	Armstrong, Shannon O, Little, Richard A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6700656/ https://www.ncbi.nlm.nih.gov/pubmed/31496665 http://dx.doi.org/10.2147/PPA.S213258

Ejemplares similares

Expanding statin use for prevention of ASCVD in Indians: Reasoned and simplified proposals
por: Enas, Enas A., et al.
Publicado: (2020)

Apolipoprotein E polymorphisms contribute to statin response in Chinese ASCVD patients with dyslipidemia
por: Zhang, Lei, et al.
Publicado: (2019)

Highlights in ASCVD Primary Prevention for 2021
por: Polonsky, Tamar S., et al.
Publicado: (2022)

Antihyperlipidemic Medication Treatment Patterns and Statin Adherence Among Patients with ASCVD in a Managed Care Plan After Release of the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol
por: Bellows, Brandon K., et al.
Publicado: (2016)

Gauging ASCVD Risk, Does Race Matter?
por: Zuo, Ming-Liang, et al.
Publicado: (2022)

Health Literacy is Essential to ASCVD Prevention in Youth
por: Mann, Harnoor K., et al.
Publicado: (2023)

Association of hyperuricemia combined with sarcopenia on ASCVD risk
por: Nie, Guqiao, et al.
Publicado: (2023)

Can adherence to antihypertensive therapy be used to promote adherence to statin therapy?
por: Chapman, Richard H, et al.
Publicado: (2009)

Combination of Endoglin and ASCVD Risk Assessment Improves Carotid Subclinical Atherosclerosis Recognition
por: Li, Qiaowei, et al.
Publicado: (2020)

Statin cost effectiveness in primary prevention: A systematic review of the recent cost-effectiveness literature in the United States
por: Mitchell, Aaron P, et al.
Publicado: (2012)

A tool to help patients visualize ASCVD risk and the potential impact of risk-lowering interventions
por: Mendez, Keegan, et al.
Publicado: (2022)

Estimated ASCVD risk according to statin use in US adults with borderline triglycerides: Results from National Health and Nutrition Examination Survey (NHANES) 2007–2014
por: Fan, Wenjun, et al.
Publicado: (2020)

The Potential Role of Biomarkers Associated with ASCVD Risk: Risk-Enhancing Biomarkers
por: Choi, Seonghoon
Publicado: (2019)

IMPACT OF THE COVID-19 PANDEMIC ON THE MANAGEMENT OF RISK FACTORS IN PATIENTS WITH ASCVD
por: Karalis, Dean, et al.
Publicado: (2023)

The costs outweigh the benefits: seeing side-effects online may decrease adherence to statins
por: Jones, Nickolas M., et al.
Publicado: (2020)

Associations Between Statin Adherence Level, Health Care Costs, and Utilization
por: Zhao, Yongming, et al.
Publicado: (2014)

Patient-Centered Interventions to Improve Adherence to Statins: A Narrative Synthesis of Systematically Identified Studies
por: Jörntén-Karlsson, Magnus, et al.
Publicado: (2016)

RELATION OF 10-YEAR ASCVD RISK SCORE WITH SEVERE COVID-19 OUTCOMES
por: Arif, Yousif, et al.
Publicado: (2022)

Newer and Emerging LDL-C Lowering Agents and Implications for ASCVD Residual Risk
por: Rikhi, Rishi, et al.
Publicado: (2022)

Analisi di costo-utilità di evolocumab in pazienti con ASCVD in Italia
por: Marcellusi, Andrea, et al.
Publicado: (2021)

Comparison of Framingham Cardiovascular Risk Criteria and ASCVD Score in Iranian Obese Patients
por: Hasani-Ranjbar, Shirin, et al.
Publicado: (2023)

Metabolomics profile and 10-year atherosclerotic cardiovascular disease (ASCVD) risk score
por: Dehghanbanadaki, Hojat, et al.
Publicado: (2023)

Cost‐effectiveness of statins for primary prevention of atherosclerotic cardiovascular disease among people living with HIV in the United States
por: Boettiger, David C, et al.
Publicado: (2021)

Patient-reported adherence to statin therapy, barriers to adherence, and perceptions of cardiovascular risk
por: Fung, Vicki, et al.
Publicado: (2018)

Improving the physician-patient cardiovascular risk dialogue to improve statin adherence
por: Casebeer, Linda, et al.
Publicado: (2009)

Determinants of the Cost-Effectiveness of Statins
por: Morrison, Alan, et al.
Publicado: (2003)

Evaluating the Cost-Effectiveness of Statins
por: Hay, Joel W.
Publicado: (2004)

Systematic Review of RCTs Assessing the Effectiveness of mHealth Interventions to Improve Statin Medication Adherence: Using the Behaviour-Change Technique Taxonomy to Identify the Techniques That Improve Adherence
por: Bond, Zoe, et al.
Publicado: (2021)

Interventions to Improve Adherence to a Hypoglycemia Protocol
por: Destree, Lani, et al.
Publicado: (2017)

Effects of weight change on apolipoprotein B-containing emerging atherosclerotic cardiovascular disease (ASCVD) risk factors
por: Dansinger, Michael L., et al.
Publicado: (2019)

Cost effectiveness of a computer-delivered intervention to improve HIV medication adherence
por: Ownby, Raymond L, et al.
Publicado: (2013)

COVID-19 associated risks of myocardial infarction in persons with familial hypercholesterolemia with or without ASCVD
por: Myers, Kelly D., et al.
Publicado: (2021)

Parâmetros Ecocardiográficos Simples podem Substituir o Cálculo do Modelo Probabilístico ASCVD?
por: Silva, Tonnison de Oliveira, et al.
Publicado: (2022)

External validation of the ACC/AHA ASCVD risk score in a Colombian population cohort
por: Rodríguez-Ariza, Carlos Daniel, et al.
Publicado: (2023)

L-Arginine, Nitric Oxide, and Endothelial Dysfunction Underlying Atherosclerotic Cardiovascular Disease (ASCVD)
por: Shimabukuro, Michio
Publicado: (2023)

MAFLD and ASCVD: Plasma Heparin Cofactor II Activity as an Anti-liver Fibrosis Biomarker
por: Shimabukuro, Michio
Publicado: (2023)

Improving Adherence to Lipid-Lowering Therapy in a Community Pharmacy Intervention Program: A Cost-Effectiveness Analysis
por: Vegter, Stefan, et al.
Publicado: (2014)

Simulation study on LDL cholesterol target attainment, treatment costs, and ASCVD events with bempedoic acid in patients at high and very-high cardiovascular risk
por: Katzmann, Julius L., et al.
Publicado: (2022)

Association of Continuity of Primary Care and Statin Adherence
por: Warren, James R., et al.
Publicado: (2015)

Comparing Guidelines for Statin Treatment in Canada and the United States
por: Hennessy, Deirdre A, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_1h1d5loquq4fagc1aj0btgqmtc